Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA (SOPH) received a notice that Daan Guido Maria Van Well, an officer, intends to sell up to 6,168 shares of Common Stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired from the issuer upon vesting of restricted stock units on July 2 and July 3, 2026.
The notice lists an aggregate market value of $46,938.48 for the securities to be sold and identifies NASDAQ as the trading market. The RSUs were originally granted by the issuer and the planned sale is for the officer’s account.
SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on September 8, 2026. The shares were sold at a weighted average price of $8.1308 per share in transactions ranging from $7.90 to $8.35, under a duly adopted Rule 10b5-1(c) trading plan. Following this sale, she directly holds 96,992 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 27, 2026 in an open-market or private transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $8.9096 per share, and Xu now holds 556,887 Ordinary Shares directly.
SOPHiA GENETICS SA (SOPH) received a notice that officer Zhenyu Xu plans to sell 14,000 shares of common stock under Rule 144. The shares, described as Founders Shares, have an indicated aggregate value of $119,420.00, with 85,127,825 common shares reported outstanding and trading on NASDAQ.
The planned sale is to be executed through Morgan Stanley Smith Barney LLC – Executive Financial Services. The notice also lists multiple prior Rule 10b5-1 plan sales of SOPHiA GENETICS common stock for Zhenyu Xu over recent months, each with specific share counts and dollar amounts.
SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on 2026-08-25. The shares were sold at a weighted average price of $8.6793 per share, in multiple trades between $8.37 and $8.84, pursuant to a Rule 10b5-1(c) trading plan. Following this transaction, Menu owned 213,387 Ordinary Shares directly.
SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on 2026-08-25 in an open market or private transaction at a weighted average price of $8.6773 per share, with individual trade prices ranging from $8.31 to $8.83. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and following this transaction she directly owns 103,242 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Technology Officer Abhimanyu Verma sold a total of 10,000 Ordinary Shares in two open-market transactions. On August 19, 2026, he sold 5,000 shares at $8.20 per share, and on August 24, 2026, he sold 5,000 shares at $8.80 per share. Both transactions were executed under a duly adopted Rule 10b5-1(c) trading plan, indicating they were pre-arranged.
SOPHiA GENETICS SA (SOPH) received a notice under Rule 144 indicating that director Kathy L. Hibbs plans to sell up to 18,750 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $158,437.50, with an approximate sale date of August 25, 2026. Shares outstanding are listed as 85,127,825, and the securities relate to Restricted Stock Units originally dated June 18, 2025.
SOPHiA GENETICS SA (SOPH) reported that Chief People Officer Manuela Valente exercised share options for 10,000 Ordinary Shares at an exercise price of $3.20 per share and, on the same date, sold 10,000 Ordinary Shares at a weighted average price of $7.9439 per share. The transactions were made pursuant to a duly adopted Rule 10b5-1(c) trading plan. The exercised options were fully vested, and following this exercise she continues to hold 554,276 derivative share options across remaining grant tranches with varying exercise prices, with the exercised option series expiring on January 1, 2029.
SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares in open-market or private transactions under a duly adopted Rule 10b5-1(c) trading plan. The sales occurred on August 19–21, 2026, at weighted average prices of $7.94, $8.41, and $8.40, each representing multiple trades within narrow price ranges.